Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Puma Biotechnology (PBYI) Net Margin (2017 - 2025)

Puma Biotechnology's Net Margin history spans 9 years, with the latest figure at 23.42% for Q4 2025.

  • For Q4 2025, Net Margin fell 4535.0% year-over-year to 23.42%; the TTM value through Sep 2025 reached 14.45%, up 490.0%, while the annual FY2024 figure was 10.38%, 122.0% up from the prior year.
  • Net Margin reached 23.42% in Q4 2025 per PBYI's latest filing, down from 16.23% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 25.23% in Q3 2024 to a low of 96.6% in Q3 2021.
  • Average Net Margin over 5 years is 0.48%, with a median of 5.18% recorded in 2025.
  • Peak YoY movement for Net Margin: soared 9597bps in 2022, then tumbled -4535bps in 2025.
  • A 5-year view of Net Margin shows it stood at 7.63% in 2021, then plummeted by -184bps to 6.4% in 2022, then skyrocketed by 366bps to 17.0% in 2023, then grew by 29bps to 21.92% in 2024, then tumbled by -207bps to 23.42% in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Net Margin are 23.42% (Q4 2025), 16.23% (Q3 2025), and 11.17% (Q2 2025).